PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...

Microbiotica has completed patient recruitment for its phase 1b trial, COMPOSER-1, evaluating MB310 in adults with ulcerative ...

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

Fresenius Kabi has entered a global licensing agreement for the commercialisation of Polpharma Biologics’s vedolizumab ...

While each person with ulcerative colitis has different dietary triggers, coffee and one of its main components, caffeine, are common culprits.

Researchers from The University of Osaka reveal that the intestinal flora works in combination with the mutated OTUD3 gene ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, ...

The interaction between a common gene variant and gut microbes may trigger chronic inflammation in ulcerative colitis, new ...

A real-world study from China shows vedolizumab is safe and effective for elderly patients with ulcerative colitis, with ...